Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.

Authors

Rebecca Rockett¹, Kerri Basile², Susan Maddocks³, Winkie Fong³, Jessica E Agius⁴, Jessica Johnson-Mackinnon⁴, Alicia Arnott², Shona Chandra³, Mailie Gall², Jenny Draper², Elena Martinez², Eby M Sim², Clement Lee², Christine Ngo², Marc Ramsperger², Andrew N Ginn², Qinning Wang², Michael Fennell², Danny Ko², H Ling Lim³, Nicky Gilroy³, Matthew V N O'Sullivan², Sharon C-A Chen², Jen Kok², Dominic E Dwyer², Vitali Sintchenko⁵

Affiliations

¹ University of Sydney, Sydney, NSW, Australia rebecca.rockett@sydney.edu.au.
² NSW Health Pathology, Sydney, NSW, Australia.
³ Western Sydney Local Health District, Westmead, NSW, Australia.
⁴ University of Sydney, Sydney, NSW, Australia.
⁵ University of Sydney, Sydney, NSW, Australia vitali.sintchenko@sydney.edu.au.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / pharmacology
Antibodies, Neutralizing* / adverse effects
Antibodies, Neutralizing* / pharmacology
COVID-19 Drug Treatment*
COVID-19* / genetics
Drug Resistance, Viral* / drug effects
Drug Resistance, Viral* / genetics
Humans
Mutation
SARS-CoV-2* / drug effects
SARS-CoV-2* / genetics

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
sotrovimab

Supplementary concepts

SARS-CoV-2 variants

Grants and funding